In a decade, Eli Lilly could be in the same place that Pfizer finds itself in today.Eli Lilly (LLY +3.44%) is executing very well right now, and Wall Street is aware of that. The stock's price-to-earnings (P/E) ratio of 50 is below its five-year average of 54, but very high on an absolute basis. For reference, the S&P 500 index has a P/E ratio of 28.5. Before you buy shares in Lilly, think about what might happen over the next decade.Why is Eli Lilly doing so well right now?The big story around Eli Lilly is ...